Date: 2015-09-07
Type of information: Grant
Company: iABC (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis) consortium including Queen\'s University Belfast (UK), Belfast Health and Social Care Trust (UK) University Medical Center Utrecht (The Netherlands) Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung (Germany) Rijksuniversiteit Groningen (The Netherlands) Servicio Madrileño de Salud (Spain) Universitair Ziekenhuis Antwerpen (Belgium) University of Dundee (UK) Institut National de la Santé et de la Recherche, Poitiers (France) Università degli Studi di Milano (Italy) Hospices Civils de Lyon (France) Medizinische Hochschule Hannover (Germany) Universiteit Antwerpen (Belgium) University of Edinburgh (UK) Royal Brompton and Harefield NHS Foundation Trust (UK) Fundació Clínic per a la Recerca Biomèdica, Barcelona (Spain) Papworth Hospital NHS Foundation Trust (UK) Erasmus Medical Center (The Netherlands) Basilea Pharmaceutica (Switzerland) Novartis (Switzerland)
Investors: Innovative Medicines Initiative (IMI) (EU)
Amount: €50 million
Funding type: grant
Planned used: The iABC (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis) consortium will develop new inhaled antibiotics to manage chronic lung infection, the main cause of disease and mortality in patients with cystic fibrosis and bronchiectasis. An inhaled formulation of Basilea\'s antibiotic BAL30072 will be developed as part of this program. BAL30072 is an investigational monosulfactam antibiotic with in-vitro and in-vivo activity against many clinically relevant multidrug-resistant Gram-negative bacteria. The five-year iABC program is part of the European New Drugs for Bad Bugs (ND4BB) program and will also establish the first European patient register for bronchiectasis, providing a platform to improve the quality of care for patients across Europe as well as making it easier to develop and trial new drugs. The University of Dundee will lead the European Bronchiectasis register, which aims to recruit 10,000 patients with lung disease around Europe into clinical research studies. This work will take advantage of the cutting-edge informatics infrastructure available at Dundee through the Health Informatics Centre and the Farr Institute.
Others: * On September 7, 2015, Basilea Pharmaceutica announced that an inhaled formulation of its antibiotic BAL30072 will be developed as part of a new Europe-wide program focusing on new antibiotics that could improve the lives of patients with cystic fibrosis and bronchiectasis. The iABC (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis) consortium involves researchers from Northern Ireland, Scotland, England, Spain, Germany, France, Italy, Belgium, the Netherlands and Switzerland. Organisations involved in the iABC consortium are Queen\'s University Belfast, Belfast Health and Social Care Trust, University Medical Center Utrecht, Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V., Hannover, Rijksuniversiteit Groningen, Servicio Madrileño de Salud, Madrid, Universitair Ziekenhuis Antwerpen, University of Dundee, Institut National de la Santé et de la Recherche, Poitiers, Università degli Studi di Milano, Hospices Civils de Lyon, Medizinische Hochschule Hannover, Universiteit Antwerpen, University of Edinburgh, Royal Brompton and Harefield NHS Foundation Trust, Fundació Clínic per a la Recerca Biomèdica, Barcelona, Papworth Hospital NHS Foundation Trust, Erasmus Medical Center, Rotterdam, and the EFPIA companies Basilea Pharmaceutica International Ltd., and Novartis. The total funding for BAL30072 related work will be approximately € 11 million of which Basilea contributes about half.
Therapeutic area: Rare diseases - Genetic diseases - Infectious diseases
